玛莱克琳生物技术公司Moleculin Biotech, Inc. （MBRX） 2023年10-K年度报告「NASDAQ」.pdf

1、 Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-K X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2023or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHAN

2、GE ACT OF For the transition period from to Commission File Number:001-37758Moleculin Biotech,Inc.(Exact name of registrant as specified in its charter)Delaware 47-4671997(State or Other Jurisdiction of (I.R.S.EmployerIncorporation or Organization)Identification Number)5300 Memorial Drive,Suite 950H

3、ouston,Texas 77007(713)300-5160(Address of Principal Executive Offices,Zip Code and Registrants Telephone Number)Securities registered pursuant to Section 12(b)of the Act:Title of Each Class Trading Symbol(s)Name of Each exchange on which registeredCommon Stock,par value$0.001 per share MBRX Nasdaq

4、Stock Market LLC Securities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No X Indicate by check mark if the registrant is not required to file reports pursuant to Section

5、13 or Section 15(d)of the Act.Yes No X Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12months(or for such shorter periods as the registrant was required to file such reports

6、)and(2)has been subject to such filing requirements for the past 90 days.Yes X No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during thepreceding 12 months(or for such shorter p